5 - Year: 2.974
Ranking & Category
- 29th of 59 in Chemistry, Medicinal
Aims & Scope
Anti-Cancer Agents in Medicinal Chemistry aims to cover all the latest and outstanding developments in medicinal chemistry and rational drug design for the discovery of anti-cancer agents.
Each issue contains a series of timely in-depth reviews and guest edited issues written by leaders in the field covering a range of current topics in cancer medicinal chemistry. The journal only considers high quality research papers for publication.
Anti-Cancer Agents in Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments in cancer drug discovery.
Science Citation Index-Expanded (SciSearch®), Journal Citation Reports/Science Edition, BIOSIS, BIOSIS Previews, BIOSIS Reviews Reports and Meetings, MEDLINE/PubMed/Index Medicus, Scopus, EMBASE/Excerpta Medica, Chemical Abstracts, ProQuest, BIOBASE, MediaFinder®-Standard Periodical Directory, Genamics JournalSeek, PubsHub, J-Gate and Dimensions.
Current Medicinal Chemistry - Anti-Cancer Agents was launched in 2001 and later renamed in 2006 as Anti-Cancer Agents in Medicinal Chemistry.
Differential Effects of Antofine N-Oxide on Solid Tumor and Leukemia Cells, 2014 : 14 (10); 1315 - 1323
Tania Bour, Xianwen Yang, Weihong Li, Francois Bernardin, Tony Kaoma, Arnaud Muller, Laurent Vallar and Andre Steinmetz
View Abstract Rights and Permissions
"All chemists and scientists will welcome Anti-Cancer Agents in Medicinal Chemistry as a fresh and vital source of information for this important field. The journal is highly recommended for essential reading."
Terrence C. Jenkins
YCR Laboratory of Drug Design, UK
I am glad to have my work published in Anti- Cancer Agents in Cancer. I found the publication process to be professional and efficient. The papers are reviewed rapidly and included promptly to Pubmed.
I highly recommend scientists to submit their papers at Bentham Science Publishers.
Dr. Juan Rafael Orozco Arroyave
(Electronic Engineering Department, Universidad de Antioquia, GITA Research Group, Colombia)
Has contributed: FAK and Nanog Cross Talk with p53 in Cancer Stem Cells